Skip to main content
×
Home
    • Aa
    • Aa
  • Get access
    Check if you have access via personal or institutional login
  • Cited by 9
  • Cited by
    This article has been cited by the following publications. This list is generated based on data provided by CrossRef.

    Huot, Philippe Fox, Susan H. and Brotchie, Jonathan M. 2015. Monoamine Reuptake Inhibitors in Parkinson’s Disease. Parkinson's Disease, Vol. 2015, p. 1.


    Gallagher, David A. and Schrag, Anette 2012. Psychosis, apathy, depression and anxiety in Parkinson's disease. Neurobiology of Disease, Vol. 46, Issue. 3, p. 581.


    Biemiller, Rachel and Richard, Irene Hegeman 2014. Managing depression in Parkinson’s patients: risk factors and clinical pearls. Neurodegenerative Disease Management, Vol. 4, Issue. 4, p. 329.


    Connolly, Barbara S and Fox, Susan H 2012. Drug treatments for the neuropsychiatric complications of Parkinson’s disease. Expert Review of Neurotherapeutics, Vol. 12, Issue. 12, p. 1439.


    QUELHAS, ROSA 2013. Psychiatric Care in Parkinson’s Disease. Journal of Psychiatric Practice, Vol. 19, Issue. 2, p. 118.


    Dyduch, Agnieszka and Załuska, Maria 2015. Depression in Parkinson's disease: the effectiveness and risk of pharmacotherapy. Clinical review. Psychogeriatrics, Vol. 15, Issue. 2, p. 147.


    Connolly, Barbara and Fox, Susan H. 2014. Treatment of Cognitive, Psychiatric, and Affective Disorders Associated with Parkinson’s Disease. Neurotherapeutics, Vol. 11, Issue. 1, p. 78.


    Cooney, Jeffrey W. and Stacy, Mark 2016. Neuropsychiatric Issues in Parkinson’s Disease. Current Neurology and Neuroscience Reports, Vol. 16, Issue. 5,


    Carvalho, Miguel M Campos, Filipa L Coimbra, Bárbara Pêgo, José M Rodrigues, Carla Lima, Rui Rodrigues, Ana J Sousa, Nuno and Salgado, António J 2013. Behavioral characterization of the 6-hydroxidopamine model of Parkinson’s disease and pharmacological rescuing of non-motor deficits. Molecular Neurodegeneration, Vol. 8, Issue. 1, p. 14.


    ×

Bupropion in the treatment of depression in Parkinson's disease

  • Maria Załuska (a1) and Agnieszka Dyduch (a2)
  • DOI: http://dx.doi.org/10.1017/S1041610210001687
  • Published online: 01 September 2010
Abstract
ABSTRACT

A 78-year-old female with a nine-year history of depression was hospitalized due to worsening depression and symptoms associated with Parkinson's disease (PD). Her motor abilities improved on levodopa and the depression improved after a trial of bupropion, following unsuccessful treatment with other antidepressants. We found four reports on successful treatment of depression in PD with bupropion. However, no controlled double-blind studies have been conducted so clinicians should be cautious when administering bupropion in depression in PD.

Copyright
Corresponding author
Correspondence should be addressed to: Agnieszka Dyduch, Oddział Psychiatrii, Szpital Bielański, Cegłowska 80, 01-809 Warsaw, Poland. Phone: +48 601 178 946; Fax. +48 22 864 47 46. Email: agabudzisz@wp.pl.
Linked references
Hide All

This list contains references from the content that can be linked to their source. For a full set of references and notes please see the PDF or HTML where available.

J. Bailey and S. Waters (2008). Acute psychosis after bupropion treatment in a healthy 28-year-old woman. Journal of the American Board of Family Medicine, 21, 244245. doi: 10.3122/jabfm.2008.03.070236.

J. A. Brommelhoff , M. Gatz , B. Johansson , J. J. McArdle , L. Fratiglioni and N. L. Pedersen (2009). Depression as a risk factor or prodromal feature for dementia? Findings in a population-based sample of Swedish twins. Psychology and Aging, 24, 373384. doi: 10.1037/a0015713.

S. Gebhardt , H. Röttgers , A. Bäcker , U. Schu and J. C. Krieg (2008). Treatment of panic disorder with bupropion in a patient with Parkinson's disease. Journal of Clinical Pharmacy and Therapeutics, 33, 575577. doi: 10.1111/j.1365-2710.2008.00952.x.

C. G. Goetz , C. M. Tanner and H. L. Klawans (1984). Bupropion in Parkinson's disease. Neurology, 34, 10921094.

F. Grandas and L. López-Manzanares (2007). Bupropion-induced parkinsonism. Movement Disorders, 22, 18301831. doi: 10.1002/mds.21425.

P. Remy , M. Doder , A. Lees , N. Turjanski and D. Brooks (2005). Depression in Parkinson's disease: loss of dopamine and noradrenaline innervation in the limbic system. Brain, 128, 13141322. doi: 10.1093/brain/awh445.

M. Shiba (2000). Anxiety disorders and depressive disorders preceding Parkinson's disease: a case-control study. Movement Disorders, 15, 669677.

W. M. Stein and S. Read (1997). Chronic pain in the setting of Parkinson's disease and depression. Journal of Pain and Symptom Management, 14, 255258. doi: 10.1016/S0885-3924(97)00176-0.

C. Veazey , S. O. Aki , K. F. Cook , E. C. Lai and M. E. Kunik (2005). Prevalence and treatment of depression in Parkinson's disease. Journal of Neuropsychiatry and Clinical Neurosciences, 17, 310323. doi: 10.1176/appi.neuropsych.17.3.310.

Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

International Psychogeriatrics
  • ISSN: 1041-6102
  • EISSN: 1741-203X
  • URL: /core/journals/international-psychogeriatrics
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×

Keywords: